Loading
A phase 3 trial of Valrubicin in Non-muscle-invasive bladder cancer, run by Endo USA Inc., a Keenova Therapeutics Company, recorded as terminated on the registry.
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder is a phase 3 interventional study registered as NCT01310803 by Endo USA Inc., a Keenova Therapeutics Company, with 1 participants recorded, started 2011-05 and due to reach its primary completion in 2012-01. Interventions recorded: VALSTAR - Maintenance Therapy, No Maintenance treatment ( Standard of Care). Conditions recorded: Carcinoma in Situ, Transitional Cell Carcinoma, Non-muscle Invasive Bladder Cancer.
Linked to the drug Valrubicin because the registry names it among its interventions and Non-muscle-invasive bladder cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Endo (now Keenova Therapeutics and Par Health) and the tag pipeline.
Shares Endo (now Keenova Therapeutics and Par Health) and the tag pipeline.
Shares Non-muscle-invasive bladder cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/